Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.66 |
| ▸ | MAOB | P27338 | 4/20 | 0.66 |
| ▸ | MAOA | P21397 | 2/20 | 0.66 |
| ▸ | BCHE | P06276 | 2/20 | 0.66 |
| ▸ | PPARG | P37231 | 1/20 | 0.60 |
| ▸ | DRD4 | P21917 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5194103 | 0.79 | L3MBTL1 (0.59) | ACHEMAOBMAOABCHEMEN1 | |
| SCHEMBL5701159 | 0.76 | PPARG (1.00) | PPARGDRD4DRD2DRD3ADRA1D | |
| SCHEMBL5193518 | 0.76 | PPARG (0.56) | ACHEMAOBMAOABCHEPPARG | |
| SCHEMBL5193310 | 0.76 | PPARG (0.56) | ACHEMAOBMAOABCHEPPARG | |
| SCHEMBL5195148 | 0.74 | ACHE (0.49) | ACHEMAOBMAOARAB9A | |
| SCHEMBL5193548 | 0.74 | PPARG (0.54) | ACHEMAOBMAOABCHEPPARG | |
| Bromide SCHEMBL5197974 | 0.73 | ACHE (0.48) | ACHEMAOBMAOARAB9A | |
| SCHEMBL7256547 | 0.73 | PPARG (0.56) | MAOAPPARGDRD4DRD2DRD3 | |
| Bromide SCHEMBL11093375 | 0.73 | BCHE (0.62) | ACHEMAOBMAOABCHEPPARG | |
| Hydrochloric Acid SCHEMBL7253613 | 0.72 | PPARG (0.55) | ACHEMAOBMAOABCHEPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1277736-B1 | NOVEL BICYCLIC COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2007-08-08 | — | — | EP | claimed |
| US-7049445-B2 | Bicyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-05-23 | — | — | US | claimed |
| US-20040127546-A1 | for treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances; beta 3-agonist | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-07-01 | — | — | US | claimed |
| US-20030191174-A1 | Eating disorders; antidiabetic agents; gastrointestinal disorders | ASAHI KASEI PHARMA CORPORATION (JP) | 2003-10-09 | — | — | US | claimed |
| EP-1277736-A1 | NOVEL BICYCLIC COMPOUNDS | Asahi Kasei Kabushiki Kaisha (JP) | 2003-01-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127546-A1 | for treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances; beta 3-agonist | GPR119, ADRB3, DBH | ACHE 1370/4885MAOB 489/4885MAOA 706/4885 |
| US-20030191174-A1 | Eating disorders; antidiabetic agents; gastrointestinal disorders | GPR119, GIPR, SLC5A2 | ACHE 3796/4885MAOB 666/4885MAOA 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.